MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
MSD's cancer immunotherapy Keytruda will soon be available as a subcutaneous injection that does away with the need to visit an infusion clinic. Keytruda Qlex (pembrolizumab and berahyaluronidase alfa ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback